August 15th 2020
By Skylar Jeremias
There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.
August 14th 2020
By Tony Hagen
Up-and-coming Henlius Biotech consolidates its footing in the biosimilar world with another regulatory approval.
By Deana Ferreri, PhD
Celltrion finds fault with a critique of equivalence margins used to approve its infliximab biosimilar.
Allowing pharmacists to independently fill prescriptions with biosimilars can offer community oncology practices a way to cut costs and increase access to cancer care for patients, according to Lucy Langer, MD.
August 13th 2020
Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.
Dismayed at the low biosimilar uptake and the lost savings, large employers are taking matters into their own hands.
August 12th 2020
Pharmacy experts discuss their level of confidence with biosimilars and some of the hurdles that stand in the way of optimizing these lower-cost medicines.
August 11th 2020
Now that Polpharma Biologics has fully integrated Bioceros into its brand, the company hopes to become one of the world’s leading biologics manufacturers.
August 10th 2020
A rituximab biosimilar in diffuse large B-cell lymphoma (DLBCL) passes the real-world test with flying colors, according to Manfred Weslau, MD.
Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.
